Articles

: Former Wells Fargo chief Tim Sloan says he was ‘scapegoat’ after fake-accounts scandal

Sloan seeks $34 million as he charges bank with using him as a "scapegoat" in a scandal that he did not cause.

: The worst gift I ever received came with the best intentions

Buyer beware: these gifts could end up actually costing the recipients money.

Washington Watch: Ukraine aid now tops $111 billion, and Biden wants $61 billion more. Where will it end?

The White House says cutting off funding to Ukraine would ‘kneecap’ Kyiv on the battlefield. Here’s what President Biden is asking for now, and the cost U.S. taxpayers have borne so far.

The Ratings Game: Nvidia’s stock is now this chip analyst’s top pick — knocking out AMD

Even with its 220% rally so far this year, Nvidia's stock is now the top large-cap pick for Piper Sandler analyst Harsh Kumar, who covers various chip and hardware stocks.

Need to Know: A top for the Nasdaq and Dow could come as early as this week, strategist says

Tom DeMark, the award-winning technical strategist, thinks the Grinch may soon snatch some of the holiday cheer in financial arkets.

Outside the Box: Here’s how to know if your mutual fund has a clear view of ESG investing

Measuring the investment horizon of stock funds.

Michael Brush: 3 reasons it’s safe to own the ‘Magnificent Seven’ stocks

Rich valuations are entirely justified.

Project Syndicate: Will higher interest rates trigger a debt crisis and cuts to Social Security and Medicare? Don’t believe it.

Deficits and high debt-to-GDP ratios are not the problem.

Futures Movers: Oil prices drop 1% as doubts linger over OPEC+ production cuts

Oil futures futures fell Monday, building on a decline last week that came after a round of voluntary production cuts announced by OPEC+ left traders skeptical about compliance.

Bond Report: Bond prices pull back after last week’s rally

Bond prices are falling after surging last week on hopes for Federal Reserve interest rate cuts.

TaxWatch: The Supreme Court could gut wealth taxes before they exist — and upend the rest of the tax code

In Moore vs. U.S., a sweeping decision that sides with the government could 'super-charge the political drive' for a wealth tax, one expert said.

: Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic

The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.
1 935 936 937 938 939 1,555